December 10, 2021 -- Rebus Bio, an Illumina Ventures-backed company, announced that it has acquired the intellectual property and related assay assets of EEL Transcriptomics, a privately held company that develops high-plex spatial transcriptomics with single-cell resolution.
Running the EEL assay on the Rebus Esper platform enables spatial transcriptomics with single-cell resolution and has the potential to scale to more than 5,000 genes. The technology is applicable to a wide range of sample types, according to the firm.
The EEL assay will be available for use on the Esper system through early access in the first half of 2022 and commercially available in June of 2022.
No terms of the agreement were disclosed.